Page last updated: 2024-12-08
n-bromoacetylethanolamine phosphate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
N-bromoacetylethanolamine phosphate: inhibits 6-phosphofructo-2-kinase; affinity labeling reagent for aldolase & other enzymes; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 188343 |
| CHEMBL ID | 4751366 |
| SCHEMBL ID | 4314679 |
| MeSH ID | M0073621 |
Synonyms (9)
| Synonym |
|---|
| 52011-43-5 |
| n-bromoacetylethanolamine phosphate |
| SCHEMBL4314679 |
| 2-[(2-bromoacetyl)amino]ethyl dihydrogen phosphate |
| acetamide, 2-bromo-n-(2-(phosphonooxy)ethyl)- |
| DTXSID60199984 |
| bromoacetamide-peg1-phosphate |
| CHEMBL4751366 |
| PD167775 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (10)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1693203 | Inhibition of Trypanosoma cruzi RPE1 assessed as residual activity at 1 mM relative to control | |||
| AID1693204 | Inhibition of Trypanosoma cruzi RPE1 assessed as residual activity at 2 mM relative to control | |||
| AID1693201 | Inhibition of Trypanosoma cruzi RPE1 assessed as residual activity at 0.2 mM relative to control | |||
| AID1693200 | Inhibition of Trypanosoma cruzi Ribose 5-phosphate isomerase type B assessed as residual activity at 2 mM using ribose 5-phosphate as substrate relative to control | |||
| AID1693210 | Cytotoxicity against mouse NIH/3T3 cells | |||
| AID1693202 | Inhibition of Trypanosoma cruzi RPE1 assessed as residual activity at 0.5 mM relative to control | |||
| AID1693209 | Trypanocidal activity against Trypanosoma cruzi trypomastigotes expressing beta galactosidase infected in NIH/3T3 cells assessed as parasite growth inhibition at >= 50 uM by reporter assay | |||
| AID1693197 | Inhibition of Trypanosoma cruzi Ribose 5-phosphate isomerase type B assessed as residual activity at 0.2 mM using ribose 5-phosphate as substrate relative to control | |||
| AID1693199 | Inhibition of Trypanosoma cruzi Ribose 5-phosphate isomerase type B assessed as residual activity at 1 mM using ribose 5-phosphate as substrate relative to control | |||
| AID1693198 | Inhibition of Trypanosoma cruzi Ribose 5-phosphate isomerase type B assessed as residual activity at 0.5 mM using ribose 5-phosphate as substrate relative to control | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (17)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (41.18) | 18.7374 |
| 1990's | 6 (35.29) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.31
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.31) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||